Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot
Code Deleted. See 81479

Official Description

Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 81433 pertains to molecular genetic testing specifically designed to identify hereditary breast cancer-related disorders. These disorders include hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer. The procedure involves a duplication/deletion analysis panel that must include analyses for specific genes: BRCA1, BRCA2, MLH1, MSH2, and STK11. This testing is crucial for individuals with a family history of these cancers, as it helps in determining the presence of genetic mutations that may increase the risk of developing these types of cancer. The analysis is performed on genetic material, typically extracted from a specimen of whole blood, and aims to detect variations in the genes that are associated with hereditary cancer syndromes. By identifying these genetic markers, healthcare providers can confirm diagnoses, guide treatment decisions, and assess the risk for family members who may also carry these inherited mutations.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 81433 is indicated for the following hereditary breast cancer-related disorders:

  • Hereditary Breast Cancer This condition is characterized by an increased risk of breast cancer due to inherited genetic mutations.
  • Hereditary Ovarian Cancer This refers to ovarian cancer that occurs in families due to genetic predispositions, often linked to mutations in specific genes.
  • Hereditary Endometrial Cancer This type of cancer is associated with inherited genetic factors that increase the risk of developing endometrial cancer.

2. Procedure

The procedure for CPT® Code 81433 involves several detailed steps to perform the duplication/deletion analysis:

  • Step 1: Specimen Collection A specimen of whole blood is collected from the patient. This blood sample serves as the source of genetic material (DNA) needed for analysis.
  • Step 2: DNA Extraction The DNA is extracted from the collected blood specimen. This process involves breaking down the cellular components to isolate the DNA for further analysis.
  • Step 3: Fragmentation The extracted DNA is fragmented using a technique called sonication. This step breaks the DNA into smaller pieces, which are necessary for the subsequent analysis.
  • Step 4: Targeted Gene Enrichment The targeted gene segments are enriched through capture hybridization. This process selectively isolates the specific genes of interest, including BRCA1, BRCA2, MLH1, MSH2, and STK11, for detailed examination.
  • Step 5: Sequencing and Analysis Massively parallel sequencing and/or microarray analysis is applied to the enriched target regions. This advanced technology allows for the detection of gene mutations by comparing the gene segments and identifying any similarities or differences.
  • Step 6: Duplication/Deletion Analysis The analysis specifically looks for duplication or deletion mutations in the targeted genes. A normal gene typically has two copies per cell, while a deletion variant would show zero or one copy, and a duplication variant would indicate three or more copies.
  • Step 7: Variant Identification In addition to the primary analysis, variants not identified by sequence analysis may be detected using different types of probe amplification, ensuring a comprehensive evaluation of the genetic material.

3. Post-Procedure

After the completion of the genetic testing procedure, the results are analyzed and interpreted by qualified healthcare professionals. The findings can confirm a diagnosis of hereditary cancer and provide critical information for guiding treatment decisions. Additionally, the results may be used to identify family members who may be at increased risk for developing cancer due to inherited germ line mutations. It is essential for patients to receive genetic counseling to understand the implications of the test results and to discuss potential preventive measures or surveillance strategies for themselves and their relatives.

Short Descr HRDTRY BRST CA-RLATD DSORDRS
Medium Descr HEREDITARY BRST CA-RELATED DUP/DEL ANALYSIS
Long Descr Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE Not applicable/unspecified.
GZ Item or service expected to be denied as not reasonable and necessary
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GA Waiver of liability statement issued as required by payer policy, individual case
Date
Action
Notes
2024-12-31 Deleted Code Deleted. See 81479
2016-01-01 Added Added
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"